(A) The number of metabolites identified with high confidence spectral database matching in whole bone marrow (WBM) samples after HILIC or reverse phase chromatography (n = 3 replicates per group …
All source data for Figure 1.
Supplementary table 1A-B.
Metabolites enriched or depleted in cells sorted using 1× phosphate buffered saline (PBS) sheath fluid vs 0.5× PBS sheath fluid (fold change >2 and false discovery rate [FDR] < 0.05). Supplementary table 1b. Metabolites enriched or depleted in cells sorted using 1× PBS sheath fluid vs 0.5× PBS sheath fluid (fold change = 1.5–2 and FDR < 0.05). Correlation analysis of metabolite levels from 1× PBS versus 0.5× PBS samples: Spearman r = 0.995, y = 1.3 × −2142387. These metabolites were not significantly enriched in any metabolic pathway by pathway enrichment analysis.
Supplementary table 2A-B.
Metabolites enriched or depleted in sorted vs pipetted AML cells (fold change >2 and false discovery rate [FDR] < 0.05). Correlation analysis of sorted versus pipetted AML samples: spearman r = 0.997, y = 1.1 × +214263. Metabolites that differed between sorted and pipetted AML cells were significantly enriched in ‘cysteine and methionine metabolism’. Supplementary table 2b. Metabolites enriched or depleted in sorted versus pipetted AML cells (fold change = 1.5–2 and FDR < 0.05).
Supplementary table 3A-B.
Metabolites enriched or depleted in sorted vs pipetted ALL cells (fold change >2 and false discovery rate [FDR] < 0.05). Correlation analysis: Spearman r = 0.999, y = 1.1 × –436390. The metabolites were not significantly enriched in any metabolic pathway. Supplementary table 3b. Metabolites enriched or depleted in sorted versus pipetted ALL cells (fold change = 1.5–2 and FDR < 0.05).
Supplementary table 4A-B.
Metabolites that significantly differed between AML and ALL cells in both sorted and pipetted samples, sorted samples only, or pipetted samples only. Metabolites that significantly differed between AML and ALL cells in both sorted and pipetted samples were significantly enriched in ‘glycerophospholipid metabolism’. No pathways were enriched among metabolites that differed in only sorted samples or only in pipetted samples. Supplementary table 4b. Metabolites that significantly differed between sorted AML and ALL cells or pipetted AML and ALL cells and for which fold change was between 1.5 and 2 in either the sorted or pipetted samples (FDR < 0.05).
Supplementary table 5.
Metabolites enriched or depleted at various time points after the incubation of cell suspensions on ice. The fold change cutoff is indicated in the left column. All are false discovery rate (FDR) < 0.05. Correlation analysis: 5 min versus 15 min: Spearman r = 0.998; 5 min versus 30 min: Spearman r = 0.996; 5 min versus 60 min: Spearman r = 0.992.
Supplementary table 6A-B.
Metabolites enriched or depleted in whole bone marrow (WBM) cells isolated from cells suspended in phosphate buffered saline (PBS) versus Hank's Buffered Salt Solution (HBSS) (fold change >2 and false discovery rate [FDR] > 0.05). Correlation analysis: Spearman r = 0.960, y = 0.92 × +1759331. These metabolites were not significantly enriched in any metabolic pathway. Supplementary table 6b. Metabolites enriched or depleted in WBM cells isolated from cells suspended in PBS versus HBSS (fold change = 1.5–2 and FDR < 0.05).
The raw metabolomic analyses from experiments comparing AML and ALL cells (Figure 1H–K).
These files contain the raw counts for each metabolite in each sample and the statistical comparisons between samples for each metabolite.
(A–D) Representative chromatograms for (A) phosphatidylcholine (PC [36:2]), (B) phosphatidylethanolamine (PE [38:6]), (C) lysophosphatidylcholine (Lyso-PC [18:0]), and (D) …
Source data for Figure 1—figure supplement 1.
(A) Metabolites significantly above background in 10,000 sorted HSC/MPPs or WBM cells (n = 3–7 replicates per treatment in each of four independent experiments; fold change >2 and false discovery …
All source data for Figure 2.
Supplementary table 1.
Metabolites enriched or depleted in sorted hematopoietic stem cell (HSC)/multipotent progenitors (MPPs) as compared to whole bone marrow (WBM) cells (fold change >2 and false discovery rate [FDR] < 0.05).
Metabolites identified by Agathocleous et al. as (A) enriched or (B) depleted in HSC/MPPs as compared to WBM cells and the results obtained for the same metabolites in the current study (data are …
(A) Schematic of glycerophospholipid metabolism and (B) list of phosphatidylcholines (PC), phosphatidylethanolamines (PE), phosphatidylserines (PS), Lyso-PCs, and Lyso-PEs detected in 10,000 …
(A–D) Bone marrow cellularity (A) and the frequencies of CD150+CD48-Lin-Sca1+c-kit+ HSCs (B), CD150-CD48-Lin-Sca1+c-kit+multipotent progenitors (MPPs) (C), and Lin-Sca1+c-kit+ cells (D) in femurs …
All source data for Figure 3.
Supplementary table 1.
Metabolites that differed between circulating melanoma cells and melanoma cells from primary subcutaneous tumors in xenografted mice (fold change >2 and p<0.05).
(A) Flow cytometry gating strategies for isolating CD150+CD48-Lin-Sca1+c-kit+ hematopoietic stem cells (HSCs; 0.0057% of bone marrow cells), CD150-CD48-Lin-Sca1+c-kit+multipotent progenitors (MPPs; …
(A) Overview of the method. (B) Metabolites detected above background in 10,000 HSCs/multipotent progenitors (MPPs) in this study (green numbers, 159 metabolites total) as compared to our prior …
All source data for Figure 4.
Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
---|---|---|---|---|
Chemical compound, drug | Phosphate Buffered Saline Tablet | Sigma | Cat# P4417-100TAB | |
Chemical compound, drug | Methanol, Optima grade for LC/MS | Fisher Scientific | Cat# A456-4 | |
Chemical compound, drug | Acetonitrile, Optima Grade for LCMS | Fisher Scientific | Cat# A955-4 | |
Chemical compound, drug | MeOH, Optima Grade for LCMS | Fisher Scientific | Cat# A456-4 | |
Chemical compound, drug | Water, Optima Grade for LCMS | Fisher Scientific | Cat# W6-4 | |
Commercial assay, kit | LS magnetic enrichment columns | Miltenyi | Cat# 130-042-401 | |
Commercial assay, kit | MidiMACS separator | Miltenyi | Cat# 130-042-301 | |
Other | Plastic microfuge tube opener | USA Scientific | Cat# 1400–1508 | For minimizing metabolite contamination when opening microfuge tubes |
Antibody | FITC anti-mouse B220, clone: RA3-6B2 (rat monoclonal) | Tonbo | Cat# 35–0452 U500, RRID:AB_2621690 | Dilution: 1:400 For bone marrow HSC isolation by flow cytometry |
Antibody | FITC anti-mouse Gr-1, clone: RB6-8C5 (rat monoclonal) | Tonbo | Cat# 35–5931 U500, RRID:AB_2621721 | Dilution: 1:400 For bone marrow HSC isolation by flow cytometry |
Antibody | FITC anti-mouse Terr119, clone: TER-119 (rat monoclonal) | Tonbo | Cat# 35–5921 U500, RRID:AB_2621720 | Dilution: 1:400 For bone marrow HSC isolation by flow cytometry |
Antibody | FITC anti-mouse CD2, clone: RM2-5 (rat monoclonal) | Tonbo | Cat# 35–0021 T100, RRID:AB_2621657 | Dilution: 1:400 For bone marrow HSC isolation by flow cytometry |
Antibody | FITC anti-mouse CD3, clone: 17A2 (rat monoclonal) | Tonbo | Cat# 35–0032 U100, RRID:AB_2621660 | Dilution: 1:400 For bone marrow HSC isolation by flow cytometry |
Antibody | FITC anti-mouse CD5, clone: 53–7.3 (rat monoclonal) | Biolegend | Cat# 100606, RRID:AB_312735 | Dilution: 1:400 For bone marrow HSC isolation by flow cytometry |
Antibody | FITC anti-mouse CD8α, clone: 53–6.7 (rat monoclonal) | Tonbo | Cat# 35–0081 U500, RRID:AB_2621671 | Dilution 1:400 For bone marrow HSC isolation by flow cytometry |
Antibody | APC-e780 anti-mouse c-kit, clone: 2B8 (rat monoclonal) | eBiosciences | Cat# 47-1171-82, RRID:AB_1272177 | Dilution: 1:200 For bone marrow HSC isolation by flow cytometry |
Antibody | PerCP-Cy5.5 anti-mouse Sca-1, clone: D7 (rat monoclonal) | BioLegend | Cat# 108124, RRID:AB_893615 | Dilution 1:200 |
Antibody | APC anti-mouse CD48, clone: HM48-1 (Armenian hamster monoclonal) | eBiosciences | Cat# 17-0481-82, RRID:AB_469408 | Dilution 1:200 |
Antibody | PE anti-mouse CD150, clone: TC15-12F12.2 (rat monoclonal) | BioLegend | Cat# 115904, RRID:AB_313683 | Dilution 1:200 |
Antibody | APC anti-Mouse CD45, clone: 30-F11 (rat monoclonal) | Tonbo | Cat# 20–0451 U100, RRID:AB_2621573 | Dilution 1:100 |
Antibody | APC anti-Mouse CD31 (PECAM-1), clone: 390 (rat monoclonal) | Biolegend | Cat# 102410, RRID:AB_312905 | Dilution 1:100 |
Antibody | APC anti-Mouse Ter119, clone: Ter119 (rat monoclonal) | Tonbo | Cat# 20–5921 U100, RRID:AB_2621609 | Dilution 1:100 |
Antibody | FITC anti-Human HLA-A, B, C, clone: G46-2.6 (mouse monoclonal) | BD Biosciences | Cat# 555552, RRID:AB_395935 | Dilution 1:20 |
Antibody | Anti-Mouse c-Kit, conjugated to para-magnetic beads, clone: 3C11 (rat monoclonal) | Miltenyi | Cat# 130-091-224, RRID:AB_2753213 | (60 µl) 60 µl beads per3 × 108 whole bone marrow cells |
Antibody | Anti-Mouse CD45, conjugated to para-magnetic beads, clone: 30-F11 (rat monoclonal) | Miltenyi | Cat# 130-052-301, RRID:AB_2877061 | (3 µl) 3 µl beads per1 × 106 whole bone marrow cells |
Chemical compound, drug | DAPI | Sigma-Aldrich | Cat# D8417-10mg | 1 µg/ml for flow cytometry |
Cell line | Human – HNT-34 AML cell line | Provided by Jian Xu’s Laboratory at Children’s Research Institute at UT Southwestern Medical Center. Original source: DSMZ | ACC 600, RRID: CVCL_2071 | |
Cell line | Human DND-41 cell line | Provided by Jian Xu’s Laboratory at Children’s Research Institute at UT Southwestern Medical Center. Original source: Hui Feng, M.D./Ph.D.; Boston University | RRID: CVCL_2022 | |
Cell line | Human melanoma xenograft M405 | Sci Trans Med 4:159ra PMCID:PMC4501487 | M405 | |
Strain, strain background | NOD.CB17-Prkdcscid Il2rgtm1Wjl/Szj (NSG) mice | Jackson laboratories | 005557, RRID:IMSR_JAX:005557 | |
Strain, strain background | C57BL/Ka Thy1.1 mice | Derived from Henry Kaplan’s laboratory at Stanford University | N/A | |
Other | ZIC-pHILIC column (2.1 × 150, 5 μm) | Millipore Sigma | Cat# 1504600001 | |
Software, algorithm | Omics Data Analyzer (ODA) | This manuscript | https://git.biohpc.swmed.edu/CRI/ODA | See Materials and methods, section ‘Statistical analysis of metabolomics data’ |
Software, algorithm | Graphpad Prism V8.3 | Graphpad | RRID:SCR_002798 | |
Software, algorithm | FlowJo V10.7.1 | BD Biosciences | RRID:SCR_008520 | |
Software, algorithm | Freestyle V1.5 | Thermo Scientific | N/A | |
Software, algorithm | Trace Finder V4.0 | Thermo Scientific | N/A | |
Software, algorithm | Compound Discoverer V3.1 | Thermo Scientific | N/A | |
Chemical compound, drug | Formic Acid Optima | Fisher | Cat# A11750 | |
Chemical compound, drug | Ammonium acetate, Optima | Fisher | Cat# A11450 | |
Chemical compound, drug | Ammonium hydroxide, Optima | Fisher scientific | Cat# A470-250 | |
Chemical compound, drug | Methotrexate | Selleck Chem | Cat# S1210 | |
Chemical compound, drug | SplashMix | Avanti | Cat# 330707 |